Tag: Hemispherian AS

Hemispherian Receives FDA IND Clearance for First-in-Class Glioblastoma Therapeutic, GLIX1

OSLO, Norway, Aug. 5, 2025 /PRNewswire/ -- Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, today announced that the U.S....

Hemispherian Receives U.S. FDA Orphan Drug Designation for GLIX1 for the Treatment of Malignant Glioma

OSLO, Norway, July 1, 2025 /PRNewswire/ -- Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, announced today that the U.S....

Hemispherian receives positive opinion for Orphan Medicinal Product Designation in the EU for GLIX1 in glioma

OSLO, Norway, June 6, 2025 /PRNewswire/ -- Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, announced today that the European...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsHemispherian AS

SkillStorm Launches Cloud & Cybersecurity Certification Tracks to Accelerate Veterans’ Civilian Careers in Tech

BriaCell Announces Proposed Effective Date of Share Consolidation

Investor Alert: Robbins LLP Informs Investors of the Lineage, Inc. Class Action Lawsuit

Tag: Hemispherian AS

Hemispherian Receives FDA IND Clearance for First-in-Class Glioblastoma Therapeutic, GLIX1

Hemispherian Receives U.S. FDA Orphan Drug Designation for GLIX1 for the Treatment of Malignant Glioma

Hemispherian receives positive opinion for Orphan Medicinal Product Designation in the EU for GLIX1 in glioma

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us